Charles River Laboratories International, Inc.

Day range

$332.17 – $347.20

Open

$337.78

Prev close

$345.37

Volume

822.3K

Market cap

$16.21B

Shares out

47.74M

P/E

—

P/S

4.05

P/B

5.71

P/FCF

43.75

ROE

-8.4%

ROA

-3.2%

Debt/Equity

0.92

Div yield

0.00%

As of Oct 22, 2026

• Investor communicationsSep 24, 2026

  On September 24, 2026, in connection with its Investor Day, Charles River Laboratories International, Inc. (the "Company") issued a press release... The Company will host its Investor Day beginning at 9:00 a.m. Eastern time today, which will be live webcast and archived on the Company's Investor Relations website. To access the webcast and corresponding slide presentation, visit http://ir.criver.com.

• Shareholder meetingsMay 11, 2026

  At the Company's Annual Meeting, the following proposals were adopted by the votes specified below. (a) The following twelve (12) directors were elected to serve until our 2027 Annual Meeting of Shareholders and received the number of votes listed opposite each of their names below.

• Guidance and outlookFeb 25, 2026

  The Company is updating its financial guidance for 2026, which was initially provided on February 18, 2026, for the impact of the planned divestitures. The updated financial guidance assumes both transactions close during the second quarter of 2026. The planned divestitures are expected to reduce reported revenue by slightly more than $200 million in 2026, including more than a 50-basis-point reduction to organic revenue growth guidance.

• Executive leadershipFeb 18, 2026

  The Company entered into an at-will employment offer letter with Mr. Coleman (the 'Offer Letter') that provides for the following material compensation terms: Base Salary: Base compensation of $800,000 annually... Bonus: Mr. Coleman will be eligible to participate in the Company's Executive Incentive Compensation Program, with a targeted bonus equal to 85% of his gross annual base salary for 2026... Equity: Mr. Coleman will be eligible to receive annual stock awards beginning in May 2026. For 2026, Mr. Coleman will receive an equity award with a grant value of $3,000,000... One-Time New Hire Cash Award: Mr. Coleman will receive a one-time new hire cash award in the gross amount of $1,875,000... One-Time New Hire Equity Award: Mr. Coleman will be granted a one-time new hire equity award with a grant value of $3,500,000.

• Guidance and outlookJan 13, 2026

  2026 Non-GAAP Operating Margin: Incremental cost savings in 2026 totaling >$100M will help to offset annual cost inflation until revenue growth reinvigorates.

• IQVIQVIA Holdings Inc.+0.00%
• RVTYRevvity, Inc.+0.00%
• TECHBio-Techne Corp.+0.00%
• TMOThermo Fisher Scientific, Inc.+0.00%
• AAgilent Technologies Inc.+0.00%
• ICLRIcon Plc+0.00%

Days to cover

2.7

Short interest

2.88M

Avg volume

1.07M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera
  positiveGlobeNewswire Inc.· Oct 12, 2026
• PGNY or CRL: Which Is the Better Value Stock Right Now?
  positiveZacks Investment Research· Oct 7, 2026
• Charles River Gains 75.8% in a Year: What's Driving the Rally?
  neutralZacks Investment Research· Oct 7, 2026
• Global Animal Model Market Report 2026-2034 by Animal Type, Technology, Application, End User, and Region | CRISPR and Drug Discovery Drive Growth to USD 3.31 Billion
  positiveGlobeNewswire Inc.· Oct 6, 2026
• Is It Prudent to Add Teleflex Stock to Your Portfolio Now?
  neutralZacks Investment Research· Oct 6, 2026